Evidence map›Paper›PMID 37791909›Full record

ArticleACS synthetic biology2023

Conditional Control of Universal CAR T Cells by Cleavable OFF-Switch Adaptors.

Michael Kvorjak, Elisa Ruffo, Yaniv Tivon, Victor So, Avani Parikh, Alexander Deiters, Jason Lohmueller

Open access · hybridAbstract read
In one paragraph

Article in ACS synthetic biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Conditionally Activatable Antibody Platforms: Mechanisms, Modalities, and Clinical Translation Potential.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  3. Small-molecule control of CAR T cells.Nature reviews. Chemistry · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Michael KvorjakUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, United States.
Elisa RuffoUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, United States.
Yaniv TivonDepartment of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States.ORCID 0000-0002-1573-4096
Victor SoUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, United States.ORCID 0000-0003-2416-3739
Avani ParikhUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, United States.ORCID 0000-0002-4083-0987
Alexander DeitersCenter for Systems Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, United States.ORCID 0000-0003-0234-9209
Jason LohmuellerUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, United States.ORCID 0000-0001-6089-9992
University of Pittsburgh · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
Cellular Approaches to Tissue Engineering/RegenerationT32EB001026 · NIBIB · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DUNCAN, ANDREW W, MONGA, SATDARSHAN SINGH · 2003 to 2024
$5.5M
Conditional control of universal antigen receptor signalingR01GM142007 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LOHMUELLER, JASON JAKOB · 2021 to 2025
$2.2M
Special BD LSRFortessaTMS10OD011925 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BORGHESI, LISA · 2012 to 2012
$383k
NCI NIH HHS P30 CA047904NIBIB NIH HHS T32 EB001026NIGMS NIH HHS R01 GM142007NIH HHS S10 OD011925
6 · The paper itself

Abstract

As living drugs, engineered T cell therapies are revolutionizing disease treatment with their unique functional capabilities. However, they suffer from limitations of potentially unpredictable behavior, toxicities, and nontraditional pharmacokinetics. Engineering conditional control mechanisms responsive to tractable stimuli such as small molecules or light is thus highly desirable. We and others previously developed "universal" chimeric antigen receptors (CARs) that interact with coadministered antibody adaptors to direct target cell killing and T cell activation. Universal CARs are of high therapeutic interest due to their ability to simultaneously target multiple antigens on the same disease or different diseases by combining with adaptors to different antigens. Here, we further enhance the programmability and potential safety of universal CAR T cells by engineering OFF-switch adaptors that can conditionally control CAR activity, including T cell activation, target cell lysis, and transgene expression, in response to a small molecule or light stimulus. Moreover, in adaptor combination assays, OFF-switch adaptors were capable of orthogonal conditional targeting of multiple antigens simultaneously, following Boolean logic. OFF-switch adaptors represent a robust new approach for the precision targeting of universal CAR T cells with potential for enhanced safety.

Indexed as

Receptors, Chimeric AntigenAntigensLymphocyte ActivationT-LymphocytesAntigensReceptors, Chimeric Antigenadoptive cell therapyCAR T cellgenetic switchimmunotherapyoptical sensoruniversal CAR

Identifiers

PMID37791909
PMCPMC10594876
OpenAlexW4387326107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.